-
11.发明申请Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US20100196313A1
公开(公告)日：2010-08-05
申请号：US12756092
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US09533124B2
公开(公告)日：2017-01-03
申请号：US13086664
申请日：2011-04-14
Applicant: Matthew M. Mack , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
Inventor： Matthew M. Mack , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
CPC classification number: A61M25/1011 , A61F2/958 , A61M25/10182 , A61M25/10185 , A61M25/10188 , A61M25/104 , A61M2025/0004 , A61M2025/0006 , A61M2025/1013 , A61M2025/1015 , A61M2025/1052 , A61M2025/1079
Abstract: A catheter configured for performing reperfusion by alternatively occluding a vessel so as to prevent fluid flow and removing that occlusion to allow fluid flow is described. A first catheter includes an outer member and a retractable valve to allow and prevent fluid flow in the vessel. A second catheter includes a sheathed expansion member that can be deployed and recaptured to prevent and allow, respectively, fluid flow. A third catheter includes an angioplasty balloon to open a vessel occlusion, in which an occlusion balloon is used to allow and disallow fluid flow. A fourth catheter includes an expandable member for providing mechanical plunging action to urge thrombotic material to a more distal location. A fifth catheter includes an accessory catheter that can be used to perform reperfusion with another catheter. A sixth catheter includes an inner balloon within an outer balloon configured to perform reperfusion.
Abstract translation: 导管，被配置为通过交替地封闭容器进行再灌注，以便防止流体流动并且去除该阻塞以允许流体流动。 第一导管包括外部构件和可伸缩阀，以允许和防止流体在容器中流动。 第二导管包括可以展开和重新捕获以防止和允许流体流动的护套膨胀构件。 第三导管包括血管成形术球囊以打开血管闭塞，其中使用阻塞气囊来允许和禁止流体流动。 第四导管包括用于提供机械插入作用以将血栓形成材料推动到更远侧位置的可扩张构件。 第五导管包括可用于对另一个导管进行再灌注的辅助导管。 第六导管包括构造成执行再灌注的外气囊内的内气球。
-
13.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US08486387B2
公开(公告)日：2013-07-16
申请号：US12756119
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US08486386B2
公开(公告)日：2013-07-16
申请号：US12756092
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
公开(公告)号：US20120237477A1
公开(公告)日：2012-09-20
申请号：US13481627
申请日：2012-05-25
Applicant: Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
Inventor： Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
CPC classification number: A61K9/0024 , A61K31/4439 , A61K31/557 , A61K31/56 , A61K38/195 , A61K38/27 , A61K38/30 , A61K47/36 , A61L27/26 , A61L27/52 , C08L5/08 , C08L89/06
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
Patent Agency Ranking
16.发明授权公开(公告)号：US08187621B2
公开(公告)日：2012-05-29
申请号：US11447340
申请日：2006-06-05
Applicant: Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
Inventor： Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
CPC classification number: A61K9/0024 , A61K31/4439 , A61K31/557 , A61K31/56 , A61K38/195 , A61K38/27 , A61K38/30 , A61K47/36 , A61L27/26 , A61L27/52 , C08L5/08 , C08L89/06
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
公开(公告)号：US20100196314A1
公开(公告)日：2010-08-05
申请号：US12756119
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
18.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 失效改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US07732190B2
公开(公告)日：2010-06-08
申请号：US11496824
申请日：2006-07-31
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US09005672B2
公开(公告)日：2015-04-14
申请号：US12016180
申请日：2008-01-17
Applicant: Eugene T. Michal , Shubhayu Basu , Alexander J. Sheehy , Francis G. Spinale , Rupak Mukherjee
Inventor： Eugene T. Michal , Shubhayu Basu , Alexander J. Sheehy , Francis G. Spinale , Rupak Mukherjee
CPC classification number: A61L27/26 , A61L27/20 , A61L27/22 , A61L27/3834 , A61L27/50 , A61L27/52 , A61L2300/418 , A61L2300/64 , A61L2400/06 , A61L2430/20 , C08L5/04 , C08L89/00
Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.
Abstract translation: 可以在足以引起心肌梗死扩张速率衰减的后心肌梗死区域中形成生物支架。 在心肌梗死后区域可进一步形成生物支架，引起左后壁壁厚度增加。 凝胶或生物支架可以由不同凝胶化系统的凝胶组分的混合物形成。 例如，生物支架可以通过混合至少两种不同的双组分凝胶化体系的至少两种不同组分形成第一混合物并通过混合至少两种不同组分（构成第一混合物的组分） 的至少两种不同的双组分凝胶化体系以形成第二混合物。
-
公开(公告)号：US08983601B2
公开(公告)日：2015-03-17
申请号：US13405909
申请日：2012-02-27
Applicant: Kiyotaka Fukamachi , Alex Massiello , Mariko Kobayashi , Ray Dessoffy , Eugene Jung , Shubhayu Basu
Inventor： Kiyotaka Fukamachi , Alex Massiello , Mariko Kobayashi , Ray Dessoffy , Eugene Jung , Shubhayu Basu
CPC classification number: A61N1/36114 , A61N1/36139 , A61N1/3627
Abstract: Treatment of heart failure in a patient by electrically modulating both the sympathetic and parasympathetic autonomic cardiac nerve fibers that innervate the patient's heart at an extravascular site in the pericardial space of the heart. The extravascular site is any suitable single location inside the chest cavity that carries both sympathetic and parasympathetic cardiac nerves such as the cardiac plexus or the pericardial transverse sinus or any two separate extravascular sites with one site carrying predominantly sympathetic cardiac nerves and the other site carrying predominantly parasympathetic cardiac nerves for electrically modulating the balance of autonomic cardiac nerve control. Physiologic inputs from a neuromodulation system's own sensors or from separate implanted or external cardiovascular hemodynamic sensor systems can be used for closed loop control over the balance of sympathetic and parasympathetic cardiac autonomic effects on the patient's cardiac function in real time response to chronic and transient physiologic needs.
Abstract translation: 通过电动调节在心脏心包空间内的血管外位置支配患者心脏的交感神经和副交感神经自主神经纤维来治疗患者的心力衰竭。 血管外部位是胸腔内任何合适的单一位置，其携带交感神经和副交感神经，如心脏神经丛或心包横向窦或任何两个分离的血管外部位，一个位点主要携带交感神经，另一个位点主要携带 副交感神经，用于电调节自主神经控制的平衡。 来自神经调节系统的自身传感器或来自分离的植入或外部心血管血液动力学传感器系统的生理输入可用于闭环控制对交感神经和副交感神经心脏自主影响对患者心脏功能的平衡，实时响应慢性和短暂的生理需求 。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.029 seconds)
